Col­orec­tal drug can­di­dates fo­cal point of new col­lab­o­ra­tion be­tween Servi­er, Cel­sius Ther­a­peu­tics

A well-known in­ter­na­tion­al phar­ma­ceu­ti­cal com­pa­ny and a rel­a­tive­ly new US pre­ci­sion ther­a­peu­tics start­up are join­ing forces to iden­ti­fy and val­i­date nov­el col­orec­tal can­cer drug tar­gets.

French phar­ma Servi­er and Cam­bridge, MA-based start­up Cel­sius Ther­a­peu­tics will work to­geth­er over a three-year pe­ri­od to re­search, de­vel­op, and com­mer­cial­ize up to three of the most promis­ing col­orec­tal can­cer drug dis­cov­ery tar­gets.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.